SlideShare a Scribd company logo
1 of 103
Download to read offline
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CRVO & NVG
MANAGEMENT 2016
INDOREDRISHTI.WORDPRESS.COM
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
DR DINESH MITTAL DR SONALEE MITTAL
DRISHTI EYE HOSP VIJAYNAGAR INDORE
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Central Retinal Vein
Occlusion
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Central Retinal Vein Occlusion
• Central retinal vein occlusion (CRVO) is a retinal vascular
condition that may cause significant ocular morbidity. It
commonly affects men and women equally and occurs
predominantly in persons over the age of 65 years. In this
population there may be associated systemic vascular
disease, including hypertension and diabetes. Younger
individuals who present with a clinical picture of CRVO may
have an underlying hypercoagulable or inflammatory
etiology. Population-based studies report prevalence of
CRVO at <0.1 to 0.4%.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Central Retinal Vein Occlusion
• CRVO is usually a unilateral disease; however, the annual risk of
developing any type of retinal vascular occlusion in the fellow eye is
approximately 1% per year, and it is estimated that up to 7% of
persons with CRVO may develop CRVO in the fellow eye within 5
years of onset in the first eye. Individuals with CRVO demonstrate a
significant decrease in vision-related quality of life with increased
healthcare costs and resource use as compared to a reference
group without ocular disease. CRVO may impact a person’s ability
to perform activities of daily living, especially in cases of bilateral
CRVO or when concurrent ocular disease limits vision in the fellow
eye.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Central Retinal Vein Occlusion
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CLINICAL FEATURES
• CRVO usually presents with sudden painless loss of vision, but it may
also present with a history of gradual visual decline that may correlate
with a series of less severe occlusions. The typical clinical constellation
in CRVO includes retinal hemorrhages (both superficial flame-shaped
and deep blot type) in all four quadrants of fundus with a dilated,
tortuous retinal venous system. The hemorrhages radiate from the optic
nerve head, are variable in quantity, and may result in the classic “blood
and thunder” appearance . Optic nerve head swelling, cotton-wool
spots, splinter hemorrhages, and macular edema are present to varying
degrees . Breakthrough vitreous hemorrhage may also be observed.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CLINICAL FEATURES
•With time, the extent of retinal hemorrhage
may decrease or resolve completely with
variable degrees of secondary RPE
alterations. The time course for resolution of
the hemorrhages varies and is dependent on
the amount of hemorrhage produced by the
occlusion. Macular edema often chronically
persists despite resolution of retinal hges .
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CLINICAL FEATURES
• An epiretinal membrane may also form.
Optociliary shunt vessels can develop on the optic
nerve head, a sign of newly formed collateral
channels with the choroidal circulation . NVD &
NVE may develop as a response to secondary
retinal ischemia. The vessels that comprise NVD
are typically of smaller caliber than optociliary
shunt vessels, branch into a vascular network
resembling a net, and will leak on FA .
Fibrovascular proliferation from NVD or NVE may
result in vitreous hemorrhage or TRD .
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CLINICAL FEATURES
•Of those with initial visual acuity of 20/40 or
better, the majority maintained this acuity.
Individuals with intermediate visual acuity
(20/50–20/200) had a variable outcome: 21%
improved to better than 20/50, 41% stayed in
the intermediate group, and 38% were worse
than 20/200. Persons with poor visual acuity
at onset (less than 20/200) had only a 20%
chance of improvement .
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CLINICAL FEATURES NVI / NVA
• Anterior-segment findings may include iris and/or angle
neovascularization (NVI/NVA). NVI typically begins at pupillary
border but may extend across the iris surface. NVA is detected
during undilated gonioscopy as fine branching vessels bridging the
scleral spur and may develop without any NVI in 6–12% of eyes
with CRVO. The CVOS used an index of any 2 clock-hours of NVI
or any NVA as evidence of significant anterior-segment NV , which
was found in 16% of eyes with 10–29 disc areas of angiographic
nonperfusion and 52% of eyes with 75 disc areas or more of
angiographic nonperfusion.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CLINICAL FEATURES
• In the CVOS, worse initial visual acuity correlated
with the development of NVI / NVA: 5% in eyes
with 20/40 or better, 14.8% in eyes with 20/50–
20/200, and 30.8% in eyes with worse than 20/200
acuity. Long-standing NVA may lead to secondary
angle closure from peripheral anterior synechiae
formation.
• Elevated IOP associated with NVI/NVA is the
hallmark of NVG .
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
PERFUSION STATUS
• The CVOS classified the perfusion status of a
CRVO as perfused, nonperfused, or
indeterminate based on fluorescein
angiographic characteristics. Angiographic
assessment of perfusion status in CRVO is
based on the photographic protocol from the
CVOS which used a conventional wide-angle
fundus camera with sweeps of the
midperiphery 30 seconds after intravenous
injection of sodium fluorescein .
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CLINICAL
FEATURES
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
FA
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
PERFUSION STATUS
• A perfused CRVO (also termed nonischemic, incomplete, or
partial) demonstrates less than 10 disc areas of retinal capillary
nonperfusion on angiography . These eyes typically have a
lesser degree of intraretinal hemorrhage on presentation.
Generally, eyes with perfused CRVO have better initial and final
visual acuity. A nonperfused CRVO (also termed ischemic,
hemorrhagic, or complete) demonstrates 10 or more disc areas
of retinal capillary nonperfusion on angiography . Acutely, these
eyes demonstrate a greater degree of intraretinal hemorrhage,
macular and disc edema, and capillary nonperfusion than in
perfused CRVO.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
PERFUSION STATUS
• A CRVO is categorized as indeterminate when
there is sufficient intraretinal hemorrhage to
prevent angiographic determination of the
perfusion status. Other examination features that
may help in determining the perfusion status in
the acute phase of a CRVO include baseline
visual acuity, presence of an afferent pupillary
defect, electroretinography (a negative waveform
may be seen), and Goldmann perimetry.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
PERFUSION STATUS
CVOS classification of initial perfusion status of the
CRVO was important for determining the natural history
of the disease. Poor visual acuity and large areas of
retinal capillary nonperfusion were significant factors
associated with an increased risk of developing
NVI/NVA. In eyes initially categorized as perfused, 10%
developed NVI/NVA compared to 35% of eyes initially
characterized as nonperfused or indeterminate. At 3
years, there was a 45% chance of developing
neovascular glaucoma after onset of ischemic CRVO.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
PERFUSION STATUS
Overall, 34% of initially perfused eyes converted
to nonperfused status after 3 years. In the
CVOS, 38 eyes (83%) with an indeterminate
CRVO at baseline were ultimately determined to
be nonperfused. Initial visual acuity was highly
correlated with degree of nonperfusion - eyes
with nonperfused CRVO were much more likely
than those with perfused CRVO to have poor
visual acuity at initial presentation and final
visit.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CLINICAL EVALUATION
• At the time of initial presentation, a careful assessment
of CRVO duration and the degree of macular edema and
retinal ischemia will determine treatment options and the
follow-up schedule. An ocular history may determine the
onset of the occlusion, although individuals may not have
noted vision loss if the fellow eye has maintained good
acuity. A history of systemic diseases, such as
hypertension, diabetes, and heart disease, and a
personal or family history of thrombosis or
hypercoagulable state should be determined.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CLINICAL EVALUATION
• The ophthalmic examination should be performed
on both eyes and include visual acuity, pupillary
reaction, and IOP . Undilated slit-lamp examination
is performed to detect NVI or NVA. Undilated
gonioscopy is essential to determine the presence
of NVA or evidence of angle closure from
peripheral anterior synechiae, as NVA may be
present without any NVI in up to 12% of eyes.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CLINICAL EVALUATION
• Ophthalmoscopic examination will help
differentiate a CRVO from intraretinal
hemorrhage associated with carotid
occlusive disease. Adjunctive imaging
studies, including OCT and FA , are helpful in
evaluating and following the presence of
macular edema and perfusion status.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
THERAPEUTIC OPTIONS
• Treatment for CRVO is directed at treating the sequelae of CRVO,
particularly macular edema and neovascularization. The recent
development of intravitreal pharmacotherapy has revolutionized the
treatment of CRVO-associated macular edema . While these
intravitreal agents can also improve secondary neovascularization,
PRP remains definitive treatment. Alternative experimental therapies
have sought to modify anatomic alterations believed to be responsible
for CRVO. Of course, management of blood pressure and other
systemic factors is always of paramount importance.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Treatment of macular edema
Observation
• The CVOS group M report studied the effect of grid
pattern argon laser photocoagulation to improve visual
acuity in 155 eyes with perfused CRVO-associated
macular edema and 20/50 acuity or worse. Laser
treatment involved a grid pattern in area of leaking
capillaries within 2 disc diameters of the foveal center
but not within the foveal avascular zone. At 36 months,
there was no significant difference in mean visual acuity
between treated (20/200) and untreated (20/160) eyes
despite reduction of angiographic macular edema.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Treatment of macular edema
• Therefore, the CVOS did not
recommend grid laser for CRVO-
associated macular edema. In the
absence of robust treatment options
before the advent of intravitreal
pharmacotherapy for retina diseases,
standard of care for CRVO-associated
macular edema was observation.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Steroids for Retinal Vein
Occlusion 2009
• The SCORE study compared the effects
of 1-mg and 4-mg intravitreal
triamcinolone acetonide (IVTA; Trivaris,
Allergan) to standard of care, which
was observation for CRVO and grid
laser for BRVO.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
SCORE-CRVO
• In SCORE-CRVO, patients received an average of 2
injections of IVTA over the course of 1 year. At the
end of year 1, 27% percent of patients who
received 1-mg IVTA and 26% of patients who
received 4-mg IVTA achieved a visual acuity gain of
3 or more lines compared with only 7% of patients
in the observation group. The visual acuity was
sustained throughout year 2. The side-effect profile
for lower dose was more favorable, however,
indicating a higher level of safety for 1-mg dose.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
The GENEVA trial published in
2010
• The GENEVA trial, published in 2010, examined the effects of the
dexamethasone intravitreal implant (Ozurdex, Allergan) in patients
with macular edema secondary to either BRVO or CRVO. The trial
enrolled 1267 patients and evenly divided them into 3 groups. The
first group received a 0.7-mg dexamethasone implant, the second
group received a 0.35-mg dexamethasone implant, and the third
group received a sham implant. The results of the study showed
that the dexamethasone implant was effective in treatment of
macular odema but with complications of cataract and glaucoma .
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
THE GENEVA TRIAL 2010
• IOP increases of 10 mm Hg or higher occurred in 32.6% of
patients; 33.7% had an IOP of 25 mm Hg or more at any
single visit, and 9.4% had an IOP of 35 mm Hg or more at
any single visit. This led to 29.1% of patients requiring
medication to lower increased IOP. In addition,1.4% and
1.7% of patients underwent glaucoma laser surgery and
glaucoma incisional surgery, respectively. Almost 16% of
patients underwent cataract extraction during the study
period. Most of these patients had some degree of lens
opacity at baseline .
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Intravitreal Anti-VEGF Agents for
Retinal Vein Occlusion
•The BRAVO and CRUISE studies, published
in 2010, evaluated the effects of
ranibizumab (Lucentis ) in patients with
macular edema secondary to BRVO and
CRVO, respectively. In both studies patients
were randomly assigned to receive monthly
injections of 0.3 mg or 0.5 mg ranibizumab
or sham injections for 6 consecutive months
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Intra
vitreal
injection
site
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Intravitreal Anti-VEGF Agents for
Retinal Vein Occlusion
• At the sixth month, patients were followed monthly and reinjected as
needed. Also at the sixth month, patients that were in sham group
were allowed to cross over to the 0.5 mg ranibizumab group. After
month 12, patients were monitored on a quarterly basis until month
24 and reinjected accordingly. Reinjection criteria were based on
OCT findings of a central subfield thickness of at least 250 μm or
signs of intraretinal fluid. In the BRAVO study, macular grid laser
rescue treatment was allowed after month 3 and could be repeated
every 3 months.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Intravitreal Anti-VEGF Agents for
Retinal Vein Occlusion
• In the first 6 months a rapid improvement in BCVA
(+18.3 letters for the 0.5 mg group, +16.6 letters
for the 0.3 mg group, and +7.3 letters for the
sham group; P < .05) that was statistically
significantly different from the sham group was
observed in both ranibizumab groups. There was
no difference between the ranibizumab groups. It
was noted that, at month 12, both ranibizumab
groups maintained the visual acuity gains of the
first 6 months .
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CRUISE trial
• The CRUISE trial had a design similar to the BRAVO
trial. The only difference was that no macular laser
treatment was allowed These results indicate that
as-needed (prn) quarterly dosing is not sufficient to
treat macular edema due to CRVO. It appears that
some eyes stabilize after a few monthly injections
and require a few injections thereafter, but vast
majority require frequent follow-up and multiple
injections to control macular edema .
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CRUISE trial
• Unlike in BRVO, the long-term outcomes in CRVO were
more guarded. Results from this study showed that 44% of
eyes had resolution of macular edema, 53% had an
improvement of 3 lines or more from CRUISE trial baseline,
and 44% of eyes had a BCVA of 20/40 or better. Eyes that
had resolution of macular edema had a statistically
significantly greater improvement in BCVA (25.2 letters vs
4.3 letters), and a statistically significantly greater
proportion achieved BCVA of 20/40 or better (64.3% vs
27.8%) compared with those eyes without resolution.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CRVO
CRVO WITH MACULAR ODEMA
INVOLVING CENTRE OF RETINA
NO
OBSERVATION
YES
INTRAVITREAL AVASTIN .
STEROIDS MAY BE
CONSIDERED
FA
OBSERVATION FOR NVE & NVD & NVI
ESP IF CNP AREA MORE THAN 10 DD AREANO NVE
NVD, NVI
NVE,NVD OR NVI PRESENT
VITREOUS HGE & NVG
PRP + ARC
NO GRID LASER
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
PRPLaser photocoagulation
• The CVOS recommended that PRP be delivered promptly after the
development of NVI/NVA but not prophylactically in eyes with
nonperfused CRVO. In approximately 90% of cases, the regression
of NVI/NVA occurs within 1–2 months of PRP. Persistent
neovascularization after PRP should be followed closely, and
additional PRP may be applied in attempts to halt its progression.
Persons presenting with NVD/NVE without NVI/NVA should be
treated with PRP to prevent anterior-segment neovascularization.
Prophylactic placement of PRP may be considered in eyes with
nonperfused CRVO and risk factors for developing NVI/NVA (male
gender, short duration of CRVO, extensive retinal nonperfusion, and
extensive retinal hemorrhage) or in cases where frequent
ophthalmologic follow-up is not possible.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CONCLUSION
• CRVO is a sight-threatening disease with
significant ocular morbidity, including macular
edema and ocular neovascularization. Before
recent advent of intravitreal pharmacotherapy
in management of CRVO, standard of care was
guided by results from CVOS, which
recommended observation of macular edema
and retinal ischemia with management of
neovascular sequelae using PRP .
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CONCLUSION
• More recently, intravitreal corticosteroids and particularly
anti-VEGF agents have demonstrated impressive
improvements in macular edema, visual acuity, and even
NV complications with a favorable side-effect profile. The
use of ranibizumab (Lucentis) and dexamethasone
implant (Ozurdex) have been FDA-approved for the
treatment of CRVO. Intravitreal pharmacotherapy has now
replaced observation as the standard of care for the
management of macular edema associated with CRVO.
BEVACIZUMAB ( AVASTIN) is used off label .
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CONCLUSION
• Results from another small study indicate that progression of retinal
nonperfusion continues, particularly in eyes in which macular edema has
not resolved.
• The authors of this study state that, in eyes with macular edema
secondary to RVO, the resolution of macular edema should not be the
sole treatment objective. The prevention of worsening retinal
nonperfusion should be a treatment objective as well. Periodic
fluorescein angiograms, preferably wide-angle, should be performed to
monitor perfusion status.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CONCLUSION
• Despite the advances in pharmacologic therapy, many eyes with RVO
continue to lose vision. The common final pathway appears to be
photoreceptor cell death. Future research for RVO treatments may
focus on neuroprotective and photoreceptor regeneration therapies to
improve sight in patients who have limited vision due to RVO.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CRVO
CRVO WITH MACULAR ODEMA
INVOLVING CENTRE OF RETINA
NO
OBSERVATION
YES
INTRAVITREAL AVASTIN .
STEROIDS MAY BE
CONSIDERED
FA
OBSERVATION FOR NVE & NVD & NVI
ESP IF CNP AREA MORE THAN 10 DD AREANO NVE
NVD, NVI
NVE,NVD OR NVI PRESENT
VITREOUS HGE & NVG
PRP + ARC
NO GRID LASER
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
NVG
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Neovascular Glaucoma
• Neovascular glaucoma (NVG) is a devastating
ocular disease often associated with poor
visual prognosis. It is a relatively common
complication of several retinal disorders,
especially CRVO, PDR , and ocular ischemic
syndrome. The pathophysiology of NVG involves
the formation of new blood vessels on the
surface of the iris and the angle of the anterior
chamber, which initially impedes aqueous
outflow, but later contracts to produce an
angle-closure form of glaucoma.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Neovascular Glaucoma
• Currently used medical or surgical treatment
has a low success rate, which has been
improved by the adjunct use of IVB. The most
effective treatment involves retinal ablation,
which reduces the level of retinal hypoxia and
slows the subsequent angiogenic cascade. The
goal of treatment should be to catch disease
early and halt the angiogenic cascade to
prevent more serious consequences of NVG.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Neovascular Glaucoma
• Approximately 36% of NVG occurs after CRVO,
32% with PDR, and 13% occurs after carotid
artery obstruction. Given that the underlying
etiology of developing NVG is some form of
retinal ischemia, it is more prevalent in elderly
patients who have significant cardiovascular
risk factors such as hypertension, diabetes,
dyslipidemia, and a history of smoking.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
NVG IN CENTRAL RETINAL VEIN
OCCLUSION
• The predominant risk factor for the
development of neovascular complications
following central retinal vein occlusion (CRVO)
is the extent, location, and duration of retinal
ischemia (ischemic drive). Whereas anterior
segment neovascularization is rare in
nonischemic CRVO, the incidence of NVI is as
high as 60% in ischemic eyes, usually occurring
at a mean of 3–5 months after the CRVO.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
NVG IN CENTRAL RETINAL VEIN
OCCLUSION
• The importance of closely following
patients with CRVO was demonstrated by
the landmark CVOS . The CVOS showed
that 15% of nonischemic CRVO could
proceed to ischemic CRVO in the first 4
months. During the next 32 months an
additional 19% of eyes were found to have
converted to the ischemic form for a total
of 34% after 3 years.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
NVG IN CENTRAL RETINAL VEIN
OCCLUSION
•The development of nonperfusion or ischemia
was most rapid in the first 4 months and
progressed continuously throughout the
entire duration of follow-up. NVI of at least
two clock hours, and/or NVA developed in 16%
of eyes. The CVOS also found that the most
important risk factor predictive of rubeosis
iridis was poor visual acuity.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
NVG IN CRVO
• In a prospective clinical and fluorescein
angiographic study of patients with CRVO, 20%
developed NVG. The eyes were classified as
having either ischemic or hyperpermeable type
of CRVO according to the extent of retinal
capillary nonperfusion demonstrated by initial
fluorescein angiogram. The risk of developing
NVG was approximately 60% in eyes with
extensive retinal ischemia.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
NVG Etiology and Pathogenesis
• In ischemic retinal disease, hypoxia induces
production of vascular endothelial growth
factor (VEGF), a vasoproliferative substance,
which acts upon healthy endothelial cells of
viable capillaries to stimulate the formation of
fragile new vessels (neovascularization). In
cases of extreme retinal hypoxia, there are
essentially very few viable retinal capillaries
available.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
NVG Etiology and Pathogenesis
• In that instance, VEGF is theorized to diffuse forward to
the nearest area of viable capillaries, namely the
posterior iris. Neovascularization buds off from the
capillaries of the posterior iris, grows along the posterior
iris, through the pupil, along the anterior surface of the
iris, and then into the angle. Once in the angle, the
neovascularization, along with its fibrovascular support
membrane, acts to both physically block the angle as well
as bridge the angle and pull the iris and cornea into
apposition, thus blocking the trabecular meshwork.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Diagnosis and Ancillary Testing
• Clinicians should perform a comprehensive
ophthalmologic exam with particular attention to
the pupillary margin . An undilated slit-lamp
examination and gonioscopy are essential for the
detection of NVI and NVA. Although NVI usually
precedes NVA, new vessels may occasionally be
found in the angle without evidence of iris
neovascularization. Fluorescein angiography of the
anterior segment and fluorescein gonio-
angiography may be contributive to the diagnosis
of early rubeosis iridis .
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Signs and Symptoms
• Depending on the severity of intraocular pressure
elevation, intraocular inflammation, and
glaucomatous optic neuropathy, patients can
present with various signs and symptoms of NVG
that include decreased vision, photophobia, corneal
edema, conjunctival injection, rubeosis, elevated
intraocular pressure, inflammation, hyphema, and
vitreous hemorrhage. If the inflammation is severe,
or the elevation in IOP is acute, the patient may
exhibit severe pain, headache, nausea, and/or
vomiting.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Stages of Neovascular Glaucoma
• The typical clinical presentation can be divided into three stages:
(1) rubeosis iridis; (2) open-angle glaucoma stage; and (3) angle-
closure glaucoma stage. These stages generally follow each other
in progression. The relevant clinical signs and symptoms are
included in this section and summarized in Table .
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
STAGE 1: RUBEOSIS IRIDIS
• At this stage tufts of rubeosis can be found at the pupillary
margin and/or rubeotic vessels may be found in the angle (Fig.
37-3). Although slit-lamp biomicroscopy can detect iris
neovascularization, iris fluorescein angiography has been
shown to be more reliable in detecting very early iris
neovascularization. Although neovascularization is usually seen
first at the peripupillary iris, a thorough gonioscopic examination
should be performed since NVA can sometimes precede
rubeosis.31 Intraocular pressure is typically normal, but can be
elevated if a preexisting open-angle glaucoma is present.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
STAGE 2: OPEN-ANGLE GLAUCOMA
• At this stage, the IOP begins to rise and stays
elevated. The elevated IOP can also rise suddenly,
causing acute-onset glaucoma. Due to the fragile
nature of the new vessels, a hyphema can also
present at this stage. The degree of rubeosis iridis
is usually more prominent and the anterior chamber
can show some level of inflammation. Gonioscopy
typically shows an open angle, but NVA can be
significant.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
STAGE 2: OPEN-ANGLE GLAUCOMA
• The NVI can be continuous with the new vessels in
the angle. Histopathologically, the hallmark of this
stage is growth of a fibrovascular membrane,
including rubeotic vessels on the iris surface that
extend over the trabecular meshwork, decreasing
aqueous outflow and increasing IOP in an
aberrantly open angle . Both inflammation in the
anterior chamber and possible hyphema can
exacerbate the disease process.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
STAGE 3: ANGLE-CLOSURE GLAUCOMA
• The contraction of the fibrovascular membrane causes
progressive angle closure, ectropion uveae, peripheral anterior
synechiae formation, and a flat, glistening appearance to the
iris. Patients will often complain of photophobia, reduced visual
acuity, acute severe pain, headache, nausea, and/or vomiting.
Rubeosis is usually severe, with possible hyphema, moderate
inflammation, and IOP as high as 60–70 mmHg. Conjunctival
injection and corneal edema are frequently present.
Fundoscopic examination may reveal optic nerve cupping. The
glaucoma at this stage is severe and usually requires some
form of surgical intervention.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Treatment Options
• The treatment of NVG varies depending on the stage of the
disease and the clarity of the media. Treatment strategies focus
on two separate but related issues: decreasing IOP and
reducing retinal ischemic drive.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
TREATMENT OF
NEOVASCULARIZATION
• Once rubeosis iridis has begun, the primary goal of
treatment is to reduce the ischemic drive of
neovascularization. This is best accomplished with
panretinal photocoagulation (PRP) to destroy
ischemic retina, minimize the eye’s oxygen
demand, and reduce the amount of VEGF being
released. PRP tends to be effective in causing
regression and involution of anterior segment
neovascularization.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
TREATMENT OF
NEOVASCULARIZATION
• In recent years, bevacizumab (Avastin [Genentech, Inc.]) has
emerged as an adjunct first-line treatment for rubeosis iridis.
Initial studies reported rapid regression of iris and angle
neovascularization in patients with NVG and refractory IOP
elevation . In the first large study using IVB, Wakabayashi et al.
showed that IVB combined with full PRP in patients with
rubeosis iridis may reduce risk of developing NVG. IVB
stabilized neovascular activity, and may help control IOP if the
angle is still open. If the angle was closed secondary to
synechiae, there was no effect on IOP.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Slit-lamp photograph before use
of Avastin in a patient with NVG
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
fluorescein photograph before use of
Avastin in a patient with NVG
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Slit-lamp photograph after use
of Avastin in a patient with NVG
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
fluorescein photograph after use of
Avastin in a patient with NVG
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
TREATMENT OF NVG
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
TREATMENT OF NVG
• Once a patient has progressed beyond the early stages of
rubeosis iridis and has elevated IOP with an open- or closed-
angle glaucoma, the primary goals of treatment are to regress
any neovascularization as described above and control IOP.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Medical Management of IOP
• If the angle is open and the eye still has relatively useful vision,
but IOP is above normal, initiate medical therapy to reduce
aqueous production. Patients may require a combination of
carbonic anhydrase inhibitors (topical or systemic), topical β-
blockers, and/or α2-agonists to control IOP. Prostaglandin
analogues are generally not recommended since there is
compromised access to the uveoscleral route. In addition, anti-
inflammatory agents such as topical steroid drops and
cycloplegic agents may be indicated to control any inflammation
and pain.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Surgical Management of IOP
• Occasionally, although the angle is open, it may not
be possible to control IOP on medical management
alone. Surgical glaucoma intervention involving
filtering surgery, drainage implants, and/or
cyclodestructive procedures may be necessary.
The majority of patients with NVG eventually need
surgical intervention to control elevated IOP. In one
review, 80% of patients, if followed long enough,
needed glaucoma surgery for elevated IOP,
regardless of prior treatment .
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Filtering Surgery
• Filtering surgery is relatively effective in controlling elevated IOP
associated with NVG, but is at risk for failure due to severe
ocular inflammation. Results from two studies involving early
trabeculectomy with mitomycin C (MMC) have shown
successful IOP control of 53% at 13 months50 and 66.7% at 28
months.51 Another study in which trabeculectomy with MMC
was performed on eyes with active NVG secondary to PDR
showed success rates of 67% at 1 year and 61.8% after 2–3
years
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Mitomycin MMC soaked sponges are
used for intraoperative application
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
(M) Subconjunctival application of
mitomycin C.
• (M1) Antimetabolites are
especially important on filter
revisions where there is
increased tendency for
scarring. Notice the pledget is
pushed posteriorly to the
premade subconjunctival
pocket
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
(M) Subconjunctival application of
mitomycin C.
• M2) This drawing shows the typical
placement pattern for the sponges,
three in this case. The authors prefer
this placement pattern for fornix or
limbal filters. Currently, the pledgets
are placed posteriorly in order to
encourage flow away from the limbus.
Excessive flow directly over the fistula
is more likely to cause the bleb to
become pale and avascular. The dose
is 0.4 mg/mL for 4 minutes for NVG.
When performing a combined cataract
and trabeculectomy, one may
consider increasing the MMC
exposure time and/or concentration.
After the MMC is removed, the area is
profusely irrigated.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Filtering Surgery
• The success rate has improved with performing adequate PRP
prior to surgery . When IVB was given preoperatively to eyes
that subsequently underwent trabeculectomy with MMC,
patients experienced decreased hyphema and increased
surgical success. At six months, 95% of IVB eyes achieved
complete success, whereas in the trabeculectomy with MMC
group only 50% achieved complete success and 75% had
qualified success, meaning they still required topical and/or oral
medications to control IOP.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Drainage Implants
• Aqueous tube shunt implants have some success in the
treatment of refractory NVG, especially in situations where
conventional filtering surgery has failed.57,58 Many
practitioners prefer using glaucoma drainage implants (GDIs)
because they are less dependent on control of intraocular
inflammation and failure of the filtering bleb. Although the initial
response to Ahmed valve and Molteno implants is relatively
good, the long-term outcome is poor.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
AGV contains a valve mechanism which must be
primed prior to insertion.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Drainage Implants
• Young patients with poor preoperative visual acuity are at risk of
surgical failure. NVG itself is a risk factor for Ahmed valve
failure and worse visual prognosis.61 Use of adjunct IVB with
aqueous shunt implants has been shown to be successful. In a
study that included 56 eyes that received IVB and PRP for
NVG, those that required subsequent incisional surgery were
less inflamed and had lower intraoperative and post-operative
hemorrhage.62 This study also confirmed previous findings that
most patients with NVG, if followed long enough, require
surgical in
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Cyclodestructive Procedures
• Cyclodestruction to reduce production of aqueous
humor can be achieved with photocoagulation or
cryotherapy. Long-term results of noncontact
neodymium : yttrium–aluminum–garnet
cyclophotocoagulation in neovascular glaucoma
showed success rates of 65%, 49.8%, and 34.8% at
1-, 3-, and 6-year follow-up, respectively. Contact
transscleral diode cyclophotocoagulation is
effective in lowering IOP in eyes with neovascular
glaucoma.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
Cyclodestructive Procedures
• However these procedures are not without risk,
including hypotony, phithisis, and vision loss.
Currently, a standardized cyclophotocoagulation
protocol in NVG has not yet been established.
Although the IOP can often be controlled, visual
outcomes are typically very poor, with the rate of
long-term visual loss in patients who have NVG
approaching nearly 50%.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
TREATMENT OF LATE STAGES OF
NEOVASCULAR GLAUCOMA
• If the eye no longer has visual potential, it is recommended to
initiate medical therapy to control IOP, including cycloplegic
agents, steroid drops for comfort, PRP if the media is clear and
IVB. If the media is cloudy, then panretinal cryotherapy and
cyclodestructive surgery to control IOP will likely be needed. In
a study of 70 patients with NVG resistant to medical and
surgical treatment that were treated with transconjunctival
cyclocryocoagulation, there was a significant decrease in IOP
and eye pain after 180 days.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
TREATMENT OF LATE STAGES OF
NEOVASCULAR GLAUCOMA
• However, if the eye has no vision and medical
therapy is not controlling the pain and discomfort,
more aggressive action may be needed such as
performing retrobulbar alcohol injection,
evisceration, or enucleation.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CONCLUSION
• CRVO is a sight-threatening disease with significant ocular
morbidity, including macular edema and ocular
neovascularization. Before the recent advent of
intravitreal pharmacotherapy in the management of CRVO,
standard of care was guided by results from the CVOS,
which recommended observation of macular edema and
retinal ischemia with management of neovascular
sequelae using PRP. In the absence of robust treatment
options for CRVO,50 other approaches, including the
administration of r-tPA, creation of CRA, and various
surgical interventions, had been reported with variable
success and often unacceptable adverse effects.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CONCLUSION
• More recently, intravitreal corticosteroids and particularly
anti-VEGF agents have demonstrated impressive
improvements in macular edema, visual acuity, and even
neovascular complications with a favorable side-effect
profile. The use of ranibizumab (Lucentis) and a sustained-
release dexamethasone implant (Ozurdex) have been FDA-
approved for the treatment of CRVO. Intravitreal
pharmacotherapy has now replaced
observation as standard of care for
management of macular edema associated
with CRVO.
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
CRVO
CRVO WITH MACULAR ODEMA
INVOLVING CENTRE OF RETINA
NO
OBSERVATION
YES
INTRAVITREAL AVASTIN .
STEROIDS MAY BE
CONSIDERED
FA
OBSERVATION FOR NVE & NVD & NVI
ESP IF CNP AREA MORE THAN 10 DD AREANO NVE
NVD, NVI
NVE,NVD OR NVI PRESENT
VITREOUS HGE & NVG
PRP + ARC
NO GRID LASER
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
THANK
YOU
DR DINESH
DR SONALEE
INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT

More Related Content

What's hot

Central Retinal Artery Occlusion
Central Retinal Artery Occlusion Central Retinal Artery Occlusion
Central Retinal Artery Occlusion Ade Wijaya
 
Retina 2 hypertensive changes crvo crao dr.k.n.jha -01.06.16
Retina 2 hypertensive changes crvo crao dr.k.n.jha -01.06.16Retina 2 hypertensive changes crvo crao dr.k.n.jha -01.06.16
Retina 2 hypertensive changes crvo crao dr.k.n.jha -01.06.16ophthalmgmcri
 
Retinal venous occlusive disease
Retinal venous occlusive diseaseRetinal venous occlusive disease
Retinal venous occlusive diseaseali maarouf
 
24. Retinal Vein Occlusion
24. Retinal Vein Occlusion24. Retinal Vein Occlusion
24. Retinal Vein Occlusionretinadoctor
 
BRANCH RETINAL VEIN OCCLUSION by Fritz Allen MD COPE ID 31524-CL
BRANCH RETINAL VEIN OCCLUSION by  Fritz Allen MD COPE ID 31524-CLBRANCH RETINAL VEIN OCCLUSION by  Fritz Allen MD COPE ID 31524-CL
BRANCH RETINAL VEIN OCCLUSION by Fritz Allen MD COPE ID 31524-CLVisionary Ophthamology
 
Branch retinal vein occlusion (BRVO)
Branch retinal vein occlusion (BRVO)Branch retinal vein occlusion (BRVO)
Branch retinal vein occlusion (BRVO)NIKHIL GOTMARE
 
Central retinal vein thrombosis
Central retinal vein thrombosisCentral retinal vein thrombosis
Central retinal vein thrombosisdrkvasantha
 
Central Retinal Vein Occlsion (CRVO)
Central Retinal Vein Occlsion (CRVO)Central Retinal Vein Occlsion (CRVO)
Central Retinal Vein Occlsion (CRVO)Yousaf Jamal Mahsood
 
Branched retinal vein occlusion
Branched retinal vein occlusionBranched retinal vein occlusion
Branched retinal vein occlusionAnjali Maheshwari
 
Retinal vein occlusion
Retinal  vein occlusionRetinal  vein occlusion
Retinal vein occlusionwaqar qabba'a
 
Branch Retinal Vein Occlsion (BRVO)
Branch Retinal Vein Occlsion (BRVO)Branch Retinal Vein Occlsion (BRVO)
Branch Retinal Vein Occlsion (BRVO)Yousaf Jamal Mahsood
 
Central retinal artery occlusion
Central retinal artery occlusionCentral retinal artery occlusion
Central retinal artery occlusionSSSIHMS-PG
 

What's hot (19)

Central retinal vein occulusion
Central retinal vein occulusionCentral retinal vein occulusion
Central retinal vein occulusion
 
Central Retinal Artery Occlusion
Central Retinal Artery Occlusion Central Retinal Artery Occlusion
Central Retinal Artery Occlusion
 
Retina 2 hypertensive changes crvo crao dr.k.n.jha -01.06.16
Retina 2 hypertensive changes crvo crao dr.k.n.jha -01.06.16Retina 2 hypertensive changes crvo crao dr.k.n.jha -01.06.16
Retina 2 hypertensive changes crvo crao dr.k.n.jha -01.06.16
 
Retinal venous occlusive disease
Retinal venous occlusive diseaseRetinal venous occlusive disease
Retinal venous occlusive disease
 
24. Retinal Vein Occlusion
24. Retinal Vein Occlusion24. Retinal Vein Occlusion
24. Retinal Vein Occlusion
 
BRANCH RETINAL VEIN OCCLUSION by Fritz Allen MD COPE ID 31524-CL
BRANCH RETINAL VEIN OCCLUSION by  Fritz Allen MD COPE ID 31524-CLBRANCH RETINAL VEIN OCCLUSION by  Fritz Allen MD COPE ID 31524-CL
BRANCH RETINAL VEIN OCCLUSION by Fritz Allen MD COPE ID 31524-CL
 
Branch retinal vein occlusion (BRVO)
Branch retinal vein occlusion (BRVO)Branch retinal vein occlusion (BRVO)
Branch retinal vein occlusion (BRVO)
 
Central retinal vein thrombosis
Central retinal vein thrombosisCentral retinal vein thrombosis
Central retinal vein thrombosis
 
Retinal artery occlusions
Retinal artery occlusionsRetinal artery occlusions
Retinal artery occlusions
 
Retinal Arterial Obstructions
Retinal Arterial ObstructionsRetinal Arterial Obstructions
Retinal Arterial Obstructions
 
Central Retinal Vein Occlsion (CRVO)
Central Retinal Vein Occlsion (CRVO)Central Retinal Vein Occlsion (CRVO)
Central Retinal Vein Occlsion (CRVO)
 
Branched retinal vein occlusion
Branched retinal vein occlusionBranched retinal vein occlusion
Branched retinal vein occlusion
 
CRAO
CRAOCRAO
CRAO
 
Retinal vein occlusions
Retinal vein occlusions Retinal vein occlusions
Retinal vein occlusions
 
Retinal vein occlusion
Retinal  vein occlusionRetinal  vein occlusion
Retinal vein occlusion
 
Branch Retinal Vein Occlsion (BRVO)
Branch Retinal Vein Occlsion (BRVO)Branch Retinal Vein Occlsion (BRVO)
Branch Retinal Vein Occlsion (BRVO)
 
Central retinal artery occlusion
Central retinal artery occlusionCentral retinal artery occlusion
Central retinal artery occlusion
 
Branch Retinal Vein Occlusion
Branch Retinal Vein Occlusion Branch Retinal Vein Occlusion
Branch Retinal Vein Occlusion
 
BRVO
BRVOBRVO
BRVO
 

Viewers also liked

Retinal Vein Occlusion Studies
Retinal Vein Occlusion StudiesRetinal Vein Occlusion Studies
Retinal Vein Occlusion StudiesRiyad Banayot
 
Crvo vs brvo by Dr.kausar ali
Crvo vs brvo by Dr.kausar aliCrvo vs brvo by Dr.kausar ali
Crvo vs brvo by Dr.kausar alikausar Ali
 
14 Essential Telemental Health Informed Consent Elements -- Maheu, September ...
14 Essential Telemental Health Informed Consent Elements -- Maheu, September ...14 Essential Telemental Health Informed Consent Elements -- Maheu, September ...
14 Essential Telemental Health Informed Consent Elements -- Maheu, September ...Marlene Maheu
 
CRVO and CRAO -JUST BASIC !
CRVO and CRAO -JUST BASIC !CRVO and CRAO -JUST BASIC !
CRVO and CRAO -JUST BASIC !Nitish Narang
 
Opt kuliah 17-18 des 2007
Opt   kuliah 17-18 des 2007Opt   kuliah 17-18 des 2007
Opt kuliah 17-18 des 2007gustieka
 
Difference between follicles &amp; papillae.
Difference between follicles &amp; papillae.Difference between follicles &amp; papillae.
Difference between follicles &amp; papillae.Kape John
 
Retina class 7th semester
Retina class 7th semesterRetina class 7th semester
Retina class 7th semesterNitish Narang
 
Different types of ophthalmic instruments
Different types of ophthalmic instrumentsDifferent types of ophthalmic instruments
Different types of ophthalmic instrumentsAkvan Foren
 
Central Retinal Vein OcclUsIon (CRUISE) Study - Cruise trial
Central Retinal  Vein OcclUsIon (CRUISE) Study - Cruise trialCentral Retinal  Vein OcclUsIon (CRUISE) Study - Cruise trial
Central Retinal Vein OcclUsIon (CRUISE) Study - Cruise trialLaxmi Eye Institute
 
Ophthalmology instruments By Prof.Dr.R.R.Deshpande
Ophthalmology instruments  By Prof.Dr.R.R.DeshpandeOphthalmology instruments  By Prof.Dr.R.R.Deshpande
Ophthalmology instruments By Prof.Dr.R.R.Deshpanderajendra deshpande
 
Viral and bacterial conjunctivitis
Viral and bacterial conjunctivitisViral and bacterial conjunctivitis
Viral and bacterial conjunctivitissourovroy36
 
Conjunctivitis final presentation
Conjunctivitis final presentationConjunctivitis final presentation
Conjunctivitis final presentationPat Brown
 
Ocular manifestations of hiv
Ocular manifestations of hivOcular manifestations of hiv
Ocular manifestations of hivBeka Aberra
 
Age-Related Macular Degeneration
Age-Related Macular DegenerationAge-Related Macular Degeneration
Age-Related Macular DegenerationHossein Mirzaie
 
Conjunctivitis
ConjunctivitisConjunctivitis
ConjunctivitisMeghna Rai
 

Viewers also liked (20)

Retinal Vein Occlusion Studies
Retinal Vein Occlusion StudiesRetinal Vein Occlusion Studies
Retinal Vein Occlusion Studies
 
Crvo vs brvo by Dr.kausar ali
Crvo vs brvo by Dr.kausar aliCrvo vs brvo by Dr.kausar ali
Crvo vs brvo by Dr.kausar ali
 
14 Essential Telemental Health Informed Consent Elements -- Maheu, September ...
14 Essential Telemental Health Informed Consent Elements -- Maheu, September ...14 Essential Telemental Health Informed Consent Elements -- Maheu, September ...
14 Essential Telemental Health Informed Consent Elements -- Maheu, September ...
 
CRVO and CRAO -JUST BASIC !
CRVO and CRAO -JUST BASIC !CRVO and CRAO -JUST BASIC !
CRVO and CRAO -JUST BASIC !
 
Opt kuliah 17-18 des 2007
Opt   kuliah 17-18 des 2007Opt   kuliah 17-18 des 2007
Opt kuliah 17-18 des 2007
 
Difference between follicles &amp; papillae.
Difference between follicles &amp; papillae.Difference between follicles &amp; papillae.
Difference between follicles &amp; papillae.
 
Pathology of conjuctiva
Pathology of conjuctivaPathology of conjuctiva
Pathology of conjuctiva
 
Retina class 7th semester
Retina class 7th semesterRetina class 7th semester
Retina class 7th semester
 
Pathology of cornea
Pathology of corneaPathology of cornea
Pathology of cornea
 
Different types of ophthalmic instruments
Different types of ophthalmic instrumentsDifferent types of ophthalmic instruments
Different types of ophthalmic instruments
 
Central Retinal Vein OcclUsIon (CRUISE) Study - Cruise trial
Central Retinal  Vein OcclUsIon (CRUISE) Study - Cruise trialCentral Retinal  Vein OcclUsIon (CRUISE) Study - Cruise trial
Central Retinal Vein OcclUsIon (CRUISE) Study - Cruise trial
 
Endophthalmitis 2016
Endophthalmitis  2016Endophthalmitis  2016
Endophthalmitis 2016
 
Ophthalmology instruments By Prof.Dr.R.R.Deshpande
Ophthalmology instruments  By Prof.Dr.R.R.DeshpandeOphthalmology instruments  By Prof.Dr.R.R.Deshpande
Ophthalmology instruments By Prof.Dr.R.R.Deshpande
 
Keratoplasty update 2016
Keratoplasty update 2016Keratoplasty update 2016
Keratoplasty update 2016
 
Conjunctivitis
ConjunctivitisConjunctivitis
Conjunctivitis
 
Viral and bacterial conjunctivitis
Viral and bacterial conjunctivitisViral and bacterial conjunctivitis
Viral and bacterial conjunctivitis
 
Conjunctivitis final presentation
Conjunctivitis final presentationConjunctivitis final presentation
Conjunctivitis final presentation
 
Ocular manifestations of hiv
Ocular manifestations of hivOcular manifestations of hiv
Ocular manifestations of hiv
 
Age-Related Macular Degeneration
Age-Related Macular DegenerationAge-Related Macular Degeneration
Age-Related Macular Degeneration
 
Conjunctivitis
ConjunctivitisConjunctivitis
Conjunctivitis
 

Similar to CRVO AND NVG MANAGEMENT 2016

Retinal vein occlusion
Retinal vein occlusionRetinal vein occlusion
Retinal vein occlusionHayder Khammas
 
Vitreous hemorrhage
Vitreous hemorrhage Vitreous hemorrhage
Vitreous hemorrhage zaidhayder3
 
Vein occlusion guidelines
Vein occlusion guidelinesVein occlusion guidelines
Vein occlusion guidelinesReyad Yossif
 
Lecture 9 ON &R.pptx
Lecture 9 ON &R.pptxLecture 9 ON &R.pptx
Lecture 9 ON &R.pptxHahLa2
 
BRVO Etiopatho, Management with studies
BRVO Etiopatho, Management with studiesBRVO Etiopatho, Management with studies
BRVO Etiopatho, Management with studiesVivek Adwe
 
5_sudden_loss_of_vision_disorders.pdf
5_sudden_loss_of_vision_disorders.pdf5_sudden_loss_of_vision_disorders.pdf
5_sudden_loss_of_vision_disorders.pdfMohamadAbusaad
 
zzzCENTRAL RETINAL VEIN OCCLUSION.pptx
zzzCENTRAL RETINAL VEIN OCCLUSION.pptxzzzCENTRAL RETINAL VEIN OCCLUSION.pptx
zzzCENTRAL RETINAL VEIN OCCLUSION.pptxHarshika Malik
 
Retinal Vascular Diseases - II
Retinal Vascular Diseases - IIRetinal Vascular Diseases - II
Retinal Vascular Diseases - IIAhmed Alsherbeny
 
Retinal vein occlusions
Retinal vein occlusionsRetinal vein occlusions
Retinal vein occlusionsDr Piyushi Sao
 
Silent killer next door beware of glaucoma
Silent killer next door beware of glaucomaSilent killer next door beware of glaucoma
Silent killer next door beware of glaucomaLaxmi Eye Institute
 
Retinal Vascular Diseases - I
Retinal Vascular Diseases - IRetinal Vascular Diseases - I
Retinal Vascular Diseases - IAhmed Alsherbeny
 
Neovascular glaucoma
Neovascular glaucomaNeovascular glaucoma
Neovascular glaucomaSSSIHMS-PG
 
Vitreous hemorrhage
Vitreous hemorrhageVitreous hemorrhage
Vitreous hemorrhagepoojamdm
 

Similar to CRVO AND NVG MANAGEMENT 2016 (20)

Retinal vein occlusions
Retinal vein occlusions Retinal vein occlusions
Retinal vein occlusions
 
Retinal vein occlusion
Retinal vein occlusionRetinal vein occlusion
Retinal vein occlusion
 
Vitreous hemorrhage
Vitreous hemorrhage Vitreous hemorrhage
Vitreous hemorrhage
 
Vein occlusion guidelines
Vein occlusion guidelinesVein occlusion guidelines
Vein occlusion guidelines
 
Lecture 9 ON &R.pptx
Lecture 9 ON &R.pptxLecture 9 ON &R.pptx
Lecture 9 ON &R.pptx
 
BRVO Etiopatho, Management with studies
BRVO Etiopatho, Management with studiesBRVO Etiopatho, Management with studies
BRVO Etiopatho, Management with studies
 
Retinal Vein Occlusion
Retinal Vein OcclusionRetinal Vein Occlusion
Retinal Vein Occlusion
 
Angioid streaks
Angioid streaksAngioid streaks
Angioid streaks
 
5_sudden_loss_of_vision_disorders.pdf
5_sudden_loss_of_vision_disorders.pdf5_sudden_loss_of_vision_disorders.pdf
5_sudden_loss_of_vision_disorders.pdf
 
Crvo management 2019 doscon
Crvo management 2019 dosconCrvo management 2019 doscon
Crvo management 2019 doscon
 
zzzCENTRAL RETINAL VEIN OCCLUSION.pptx
zzzCENTRAL RETINAL VEIN OCCLUSION.pptxzzzCENTRAL RETINAL VEIN OCCLUSION.pptx
zzzCENTRAL RETINAL VEIN OCCLUSION.pptx
 
Retinal Vascular Diseases - II
Retinal Vascular Diseases - IIRetinal Vascular Diseases - II
Retinal Vascular Diseases - II
 
Retinal vein occlusion
Retinal vein occlusion Retinal vein occlusion
Retinal vein occlusion
 
Retinal vein occlusion
Retinal vein occlusionRetinal vein occlusion
Retinal vein occlusion
 
Retinal vein occlusions
Retinal vein occlusionsRetinal vein occlusions
Retinal vein occlusions
 
Retinal detachment 2016
Retinal detachment 2016Retinal detachment 2016
Retinal detachment 2016
 
Silent killer next door beware of glaucoma
Silent killer next door beware of glaucomaSilent killer next door beware of glaucoma
Silent killer next door beware of glaucoma
 
Retinal Vascular Diseases - I
Retinal Vascular Diseases - IRetinal Vascular Diseases - I
Retinal Vascular Diseases - I
 
Neovascular glaucoma
Neovascular glaucomaNeovascular glaucoma
Neovascular glaucoma
 
Vitreous hemorrhage
Vitreous hemorrhageVitreous hemorrhage
Vitreous hemorrhage
 

More from DINESH and SONALEE

Epidemiology of diabetic retinopathy
Epidemiology of diabetic retinopathyEpidemiology of diabetic retinopathy
Epidemiology of diabetic retinopathyDINESH and SONALEE
 
Diabetic retinopathy management
Diabetic retinopathy management  Diabetic retinopathy management
Diabetic retinopathy management DINESH and SONALEE
 
SURFACE ABLATION PRK , LASIK , SMILE
SURFACE ABLATION PRK , LASIK , SMILESURFACE ABLATION PRK , LASIK , SMILE
SURFACE ABLATION PRK , LASIK , SMILEDINESH and SONALEE
 
General medicine update for every doctor hypertension
General medicine update for every doctor hypertensionGeneral medicine update for every doctor hypertension
General medicine update for every doctor hypertensionDINESH and SONALEE
 
General medicine update for every doctor
General medicine update for every doctorGeneral medicine update for every doctor
General medicine update for every doctorDINESH and SONALEE
 
Intravitreal injection avastin facts and myths
Intravitreal injection avastin facts and mythsIntravitreal injection avastin facts and myths
Intravitreal injection avastin facts and mythsDINESH and SONALEE
 
Diabetic macular odema update 2016
Diabetic macular odema update 2016Diabetic macular odema update 2016
Diabetic macular odema update 2016DINESH and SONALEE
 
Iol power calculation normal and post lasik eyes
Iol power calculation normal and post lasik eyesIol power calculation normal and post lasik eyes
Iol power calculation normal and post lasik eyesDINESH and SONALEE
 
LASIK REFRACTIVE SURGERY DEMYSTIFIED
LASIK REFRACTIVE SURGERY DEMYSTIFIEDLASIK REFRACTIVE SURGERY DEMYSTIFIED
LASIK REFRACTIVE SURGERY DEMYSTIFIEDDINESH and SONALEE
 

More from DINESH and SONALEE (20)

Epidemiology of diabetic retinopathy
Epidemiology of diabetic retinopathyEpidemiology of diabetic retinopathy
Epidemiology of diabetic retinopathy
 
Telemedicne in india 2020
Telemedicne in india 2020Telemedicne in india 2020
Telemedicne in india 2020
 
Oct demystified
Oct demystified  Oct demystified
Oct demystified
 
Diabetic retinopathy management
Diabetic retinopathy management  Diabetic retinopathy management
Diabetic retinopathy management
 
SURFACE ABLATION PRK , LASIK , SMILE
SURFACE ABLATION PRK , LASIK , SMILESURFACE ABLATION PRK , LASIK , SMILE
SURFACE ABLATION PRK , LASIK , SMILE
 
Pentacam demystified 2016
Pentacam demystified 2016Pentacam demystified 2016
Pentacam demystified 2016
 
Intravitreal injection
Intravitreal  injectionIntravitreal  injection
Intravitreal injection
 
Neuro ophthalmology 2016
Neuro ophthalmology  2016Neuro ophthalmology  2016
Neuro ophthalmology 2016
 
Keratitis 2016
Keratitis 2016Keratitis 2016
Keratitis 2016
 
General medicine update for every doctor hypertension
General medicine update for every doctor hypertensionGeneral medicine update for every doctor hypertension
General medicine update for every doctor hypertension
 
ARMD 2016
ARMD 2016ARMD 2016
ARMD 2016
 
General medicine update for every doctor
General medicine update for every doctorGeneral medicine update for every doctor
General medicine update for every doctor
 
Intravitreal injection avastin facts and myths
Intravitreal injection avastin facts and mythsIntravitreal injection avastin facts and myths
Intravitreal injection avastin facts and myths
 
Glaucoma management 2016
Glaucoma management 2016Glaucoma management 2016
Glaucoma management 2016
 
Diabetic macular odema update 2016
Diabetic macular odema update 2016Diabetic macular odema update 2016
Diabetic macular odema update 2016
 
Keratoconus 2016
Keratoconus 2016Keratoconus 2016
Keratoconus 2016
 
Strabismus demystified
Strabismus demystifiedStrabismus demystified
Strabismus demystified
 
Cataract surgery revisited
Cataract surgery revisitedCataract surgery revisited
Cataract surgery revisited
 
Iol power calculation normal and post lasik eyes
Iol power calculation normal and post lasik eyesIol power calculation normal and post lasik eyes
Iol power calculation normal and post lasik eyes
 
LASIK REFRACTIVE SURGERY DEMYSTIFIED
LASIK REFRACTIVE SURGERY DEMYSTIFIEDLASIK REFRACTIVE SURGERY DEMYSTIFIED
LASIK REFRACTIVE SURGERY DEMYSTIFIED
 

Recently uploaded

SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxLikeways
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...Ganesan Yogananthem
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfMedicoseAcademics
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisNilofarRasheed1
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).kishan singh tomar
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 

Recently uploaded (20)

SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdf
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid Arthritis
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 

CRVO AND NVG MANAGEMENT 2016

  • 1. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CRVO & NVG MANAGEMENT 2016 INDOREDRISHTI.WORDPRESS.COM
  • 2. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT DR DINESH MITTAL DR SONALEE MITTAL DRISHTI EYE HOSP VIJAYNAGAR INDORE
  • 3. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Central Retinal Vein Occlusion
  • 4. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
  • 5. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Central Retinal Vein Occlusion • Central retinal vein occlusion (CRVO) is a retinal vascular condition that may cause significant ocular morbidity. It commonly affects men and women equally and occurs predominantly in persons over the age of 65 years. In this population there may be associated systemic vascular disease, including hypertension and diabetes. Younger individuals who present with a clinical picture of CRVO may have an underlying hypercoagulable or inflammatory etiology. Population-based studies report prevalence of CRVO at <0.1 to 0.4%.
  • 6. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Central Retinal Vein Occlusion • CRVO is usually a unilateral disease; however, the annual risk of developing any type of retinal vascular occlusion in the fellow eye is approximately 1% per year, and it is estimated that up to 7% of persons with CRVO may develop CRVO in the fellow eye within 5 years of onset in the first eye. Individuals with CRVO demonstrate a significant decrease in vision-related quality of life with increased healthcare costs and resource use as compared to a reference group without ocular disease. CRVO may impact a person’s ability to perform activities of daily living, especially in cases of bilateral CRVO or when concurrent ocular disease limits vision in the fellow eye.
  • 7. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Central Retinal Vein Occlusion
  • 8. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
  • 9. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CLINICAL FEATURES • CRVO usually presents with sudden painless loss of vision, but it may also present with a history of gradual visual decline that may correlate with a series of less severe occlusions. The typical clinical constellation in CRVO includes retinal hemorrhages (both superficial flame-shaped and deep blot type) in all four quadrants of fundus with a dilated, tortuous retinal venous system. The hemorrhages radiate from the optic nerve head, are variable in quantity, and may result in the classic “blood and thunder” appearance . Optic nerve head swelling, cotton-wool spots, splinter hemorrhages, and macular edema are present to varying degrees . Breakthrough vitreous hemorrhage may also be observed.
  • 10. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CLINICAL FEATURES •With time, the extent of retinal hemorrhage may decrease or resolve completely with variable degrees of secondary RPE alterations. The time course for resolution of the hemorrhages varies and is dependent on the amount of hemorrhage produced by the occlusion. Macular edema often chronically persists despite resolution of retinal hges .
  • 11. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CLINICAL FEATURES • An epiretinal membrane may also form. Optociliary shunt vessels can develop on the optic nerve head, a sign of newly formed collateral channels with the choroidal circulation . NVD & NVE may develop as a response to secondary retinal ischemia. The vessels that comprise NVD are typically of smaller caliber than optociliary shunt vessels, branch into a vascular network resembling a net, and will leak on FA . Fibrovascular proliferation from NVD or NVE may result in vitreous hemorrhage or TRD .
  • 12. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
  • 13. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
  • 14. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CLINICAL FEATURES •Of those with initial visual acuity of 20/40 or better, the majority maintained this acuity. Individuals with intermediate visual acuity (20/50–20/200) had a variable outcome: 21% improved to better than 20/50, 41% stayed in the intermediate group, and 38% were worse than 20/200. Persons with poor visual acuity at onset (less than 20/200) had only a 20% chance of improvement .
  • 15. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CLINICAL FEATURES NVI / NVA • Anterior-segment findings may include iris and/or angle neovascularization (NVI/NVA). NVI typically begins at pupillary border but may extend across the iris surface. NVA is detected during undilated gonioscopy as fine branching vessels bridging the scleral spur and may develop without any NVI in 6–12% of eyes with CRVO. The CVOS used an index of any 2 clock-hours of NVI or any NVA as evidence of significant anterior-segment NV , which was found in 16% of eyes with 10–29 disc areas of angiographic nonperfusion and 52% of eyes with 75 disc areas or more of angiographic nonperfusion.
  • 16. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CLINICAL FEATURES • In the CVOS, worse initial visual acuity correlated with the development of NVI / NVA: 5% in eyes with 20/40 or better, 14.8% in eyes with 20/50– 20/200, and 30.8% in eyes with worse than 20/200 acuity. Long-standing NVA may lead to secondary angle closure from peripheral anterior synechiae formation. • Elevated IOP associated with NVI/NVA is the hallmark of NVG .
  • 17. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
  • 18. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT PERFUSION STATUS • The CVOS classified the perfusion status of a CRVO as perfused, nonperfused, or indeterminate based on fluorescein angiographic characteristics. Angiographic assessment of perfusion status in CRVO is based on the photographic protocol from the CVOS which used a conventional wide-angle fundus camera with sweeps of the midperiphery 30 seconds after intravenous injection of sodium fluorescein .
  • 19. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CLINICAL FEATURES
  • 20. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT FA
  • 21. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT PERFUSION STATUS • A perfused CRVO (also termed nonischemic, incomplete, or partial) demonstrates less than 10 disc areas of retinal capillary nonperfusion on angiography . These eyes typically have a lesser degree of intraretinal hemorrhage on presentation. Generally, eyes with perfused CRVO have better initial and final visual acuity. A nonperfused CRVO (also termed ischemic, hemorrhagic, or complete) demonstrates 10 or more disc areas of retinal capillary nonperfusion on angiography . Acutely, these eyes demonstrate a greater degree of intraretinal hemorrhage, macular and disc edema, and capillary nonperfusion than in perfused CRVO.
  • 22. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
  • 23. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT PERFUSION STATUS • A CRVO is categorized as indeterminate when there is sufficient intraretinal hemorrhage to prevent angiographic determination of the perfusion status. Other examination features that may help in determining the perfusion status in the acute phase of a CRVO include baseline visual acuity, presence of an afferent pupillary defect, electroretinography (a negative waveform may be seen), and Goldmann perimetry.
  • 24. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT PERFUSION STATUS CVOS classification of initial perfusion status of the CRVO was important for determining the natural history of the disease. Poor visual acuity and large areas of retinal capillary nonperfusion were significant factors associated with an increased risk of developing NVI/NVA. In eyes initially categorized as perfused, 10% developed NVI/NVA compared to 35% of eyes initially characterized as nonperfused or indeterminate. At 3 years, there was a 45% chance of developing neovascular glaucoma after onset of ischemic CRVO.
  • 25. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
  • 26. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT PERFUSION STATUS Overall, 34% of initially perfused eyes converted to nonperfused status after 3 years. In the CVOS, 38 eyes (83%) with an indeterminate CRVO at baseline were ultimately determined to be nonperfused. Initial visual acuity was highly correlated with degree of nonperfusion - eyes with nonperfused CRVO were much more likely than those with perfused CRVO to have poor visual acuity at initial presentation and final visit.
  • 27. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
  • 28. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CLINICAL EVALUATION • At the time of initial presentation, a careful assessment of CRVO duration and the degree of macular edema and retinal ischemia will determine treatment options and the follow-up schedule. An ocular history may determine the onset of the occlusion, although individuals may not have noted vision loss if the fellow eye has maintained good acuity. A history of systemic diseases, such as hypertension, diabetes, and heart disease, and a personal or family history of thrombosis or hypercoagulable state should be determined.
  • 29. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CLINICAL EVALUATION • The ophthalmic examination should be performed on both eyes and include visual acuity, pupillary reaction, and IOP . Undilated slit-lamp examination is performed to detect NVI or NVA. Undilated gonioscopy is essential to determine the presence of NVA or evidence of angle closure from peripheral anterior synechiae, as NVA may be present without any NVI in up to 12% of eyes.
  • 30. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CLINICAL EVALUATION • Ophthalmoscopic examination will help differentiate a CRVO from intraretinal hemorrhage associated with carotid occlusive disease. Adjunctive imaging studies, including OCT and FA , are helpful in evaluating and following the presence of macular edema and perfusion status.
  • 31. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT THERAPEUTIC OPTIONS • Treatment for CRVO is directed at treating the sequelae of CRVO, particularly macular edema and neovascularization. The recent development of intravitreal pharmacotherapy has revolutionized the treatment of CRVO-associated macular edema . While these intravitreal agents can also improve secondary neovascularization, PRP remains definitive treatment. Alternative experimental therapies have sought to modify anatomic alterations believed to be responsible for CRVO. Of course, management of blood pressure and other systemic factors is always of paramount importance.
  • 32. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
  • 33. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Treatment of macular edema Observation • The CVOS group M report studied the effect of grid pattern argon laser photocoagulation to improve visual acuity in 155 eyes with perfused CRVO-associated macular edema and 20/50 acuity or worse. Laser treatment involved a grid pattern in area of leaking capillaries within 2 disc diameters of the foveal center but not within the foveal avascular zone. At 36 months, there was no significant difference in mean visual acuity between treated (20/200) and untreated (20/160) eyes despite reduction of angiographic macular edema.
  • 34. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Treatment of macular edema • Therefore, the CVOS did not recommend grid laser for CRVO- associated macular edema. In the absence of robust treatment options before the advent of intravitreal pharmacotherapy for retina diseases, standard of care for CRVO-associated macular edema was observation.
  • 35. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Steroids for Retinal Vein Occlusion 2009 • The SCORE study compared the effects of 1-mg and 4-mg intravitreal triamcinolone acetonide (IVTA; Trivaris, Allergan) to standard of care, which was observation for CRVO and grid laser for BRVO.
  • 36. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT SCORE-CRVO • In SCORE-CRVO, patients received an average of 2 injections of IVTA over the course of 1 year. At the end of year 1, 27% percent of patients who received 1-mg IVTA and 26% of patients who received 4-mg IVTA achieved a visual acuity gain of 3 or more lines compared with only 7% of patients in the observation group. The visual acuity was sustained throughout year 2. The side-effect profile for lower dose was more favorable, however, indicating a higher level of safety for 1-mg dose.
  • 37. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT The GENEVA trial published in 2010 • The GENEVA trial, published in 2010, examined the effects of the dexamethasone intravitreal implant (Ozurdex, Allergan) in patients with macular edema secondary to either BRVO or CRVO. The trial enrolled 1267 patients and evenly divided them into 3 groups. The first group received a 0.7-mg dexamethasone implant, the second group received a 0.35-mg dexamethasone implant, and the third group received a sham implant. The results of the study showed that the dexamethasone implant was effective in treatment of macular odema but with complications of cataract and glaucoma .
  • 38. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT THE GENEVA TRIAL 2010 • IOP increases of 10 mm Hg or higher occurred in 32.6% of patients; 33.7% had an IOP of 25 mm Hg or more at any single visit, and 9.4% had an IOP of 35 mm Hg or more at any single visit. This led to 29.1% of patients requiring medication to lower increased IOP. In addition,1.4% and 1.7% of patients underwent glaucoma laser surgery and glaucoma incisional surgery, respectively. Almost 16% of patients underwent cataract extraction during the study period. Most of these patients had some degree of lens opacity at baseline .
  • 39. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Intravitreal Anti-VEGF Agents for Retinal Vein Occlusion •The BRAVO and CRUISE studies, published in 2010, evaluated the effects of ranibizumab (Lucentis ) in patients with macular edema secondary to BRVO and CRVO, respectively. In both studies patients were randomly assigned to receive monthly injections of 0.3 mg or 0.5 mg ranibizumab or sham injections for 6 consecutive months
  • 40. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Intra vitreal injection site
  • 41. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Intravitreal Anti-VEGF Agents for Retinal Vein Occlusion • At the sixth month, patients were followed monthly and reinjected as needed. Also at the sixth month, patients that were in sham group were allowed to cross over to the 0.5 mg ranibizumab group. After month 12, patients were monitored on a quarterly basis until month 24 and reinjected accordingly. Reinjection criteria were based on OCT findings of a central subfield thickness of at least 250 μm or signs of intraretinal fluid. In the BRAVO study, macular grid laser rescue treatment was allowed after month 3 and could be repeated every 3 months.
  • 42. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Intravitreal Anti-VEGF Agents for Retinal Vein Occlusion • In the first 6 months a rapid improvement in BCVA (+18.3 letters for the 0.5 mg group, +16.6 letters for the 0.3 mg group, and +7.3 letters for the sham group; P < .05) that was statistically significantly different from the sham group was observed in both ranibizumab groups. There was no difference between the ranibizumab groups. It was noted that, at month 12, both ranibizumab groups maintained the visual acuity gains of the first 6 months .
  • 43. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CRUISE trial • The CRUISE trial had a design similar to the BRAVO trial. The only difference was that no macular laser treatment was allowed These results indicate that as-needed (prn) quarterly dosing is not sufficient to treat macular edema due to CRVO. It appears that some eyes stabilize after a few monthly injections and require a few injections thereafter, but vast majority require frequent follow-up and multiple injections to control macular edema .
  • 44. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CRUISE trial • Unlike in BRVO, the long-term outcomes in CRVO were more guarded. Results from this study showed that 44% of eyes had resolution of macular edema, 53% had an improvement of 3 lines or more from CRUISE trial baseline, and 44% of eyes had a BCVA of 20/40 or better. Eyes that had resolution of macular edema had a statistically significantly greater improvement in BCVA (25.2 letters vs 4.3 letters), and a statistically significantly greater proportion achieved BCVA of 20/40 or better (64.3% vs 27.8%) compared with those eyes without resolution.
  • 45. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CRVO CRVO WITH MACULAR ODEMA INVOLVING CENTRE OF RETINA NO OBSERVATION YES INTRAVITREAL AVASTIN . STEROIDS MAY BE CONSIDERED FA OBSERVATION FOR NVE & NVD & NVI ESP IF CNP AREA MORE THAN 10 DD AREANO NVE NVD, NVI NVE,NVD OR NVI PRESENT VITREOUS HGE & NVG PRP + ARC NO GRID LASER
  • 46. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT PRPLaser photocoagulation • The CVOS recommended that PRP be delivered promptly after the development of NVI/NVA but not prophylactically in eyes with nonperfused CRVO. In approximately 90% of cases, the regression of NVI/NVA occurs within 1–2 months of PRP. Persistent neovascularization after PRP should be followed closely, and additional PRP may be applied in attempts to halt its progression. Persons presenting with NVD/NVE without NVI/NVA should be treated with PRP to prevent anterior-segment neovascularization. Prophylactic placement of PRP may be considered in eyes with nonperfused CRVO and risk factors for developing NVI/NVA (male gender, short duration of CRVO, extensive retinal nonperfusion, and extensive retinal hemorrhage) or in cases where frequent ophthalmologic follow-up is not possible.
  • 47. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CONCLUSION • CRVO is a sight-threatening disease with significant ocular morbidity, including macular edema and ocular neovascularization. Before recent advent of intravitreal pharmacotherapy in management of CRVO, standard of care was guided by results from CVOS, which recommended observation of macular edema and retinal ischemia with management of neovascular sequelae using PRP .
  • 48. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CONCLUSION • More recently, intravitreal corticosteroids and particularly anti-VEGF agents have demonstrated impressive improvements in macular edema, visual acuity, and even NV complications with a favorable side-effect profile. The use of ranibizumab (Lucentis) and dexamethasone implant (Ozurdex) have been FDA-approved for the treatment of CRVO. Intravitreal pharmacotherapy has now replaced observation as the standard of care for the management of macular edema associated with CRVO. BEVACIZUMAB ( AVASTIN) is used off label .
  • 49. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CONCLUSION • Results from another small study indicate that progression of retinal nonperfusion continues, particularly in eyes in which macular edema has not resolved. • The authors of this study state that, in eyes with macular edema secondary to RVO, the resolution of macular edema should not be the sole treatment objective. The prevention of worsening retinal nonperfusion should be a treatment objective as well. Periodic fluorescein angiograms, preferably wide-angle, should be performed to monitor perfusion status.
  • 50. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CONCLUSION • Despite the advances in pharmacologic therapy, many eyes with RVO continue to lose vision. The common final pathway appears to be photoreceptor cell death. Future research for RVO treatments may focus on neuroprotective and photoreceptor regeneration therapies to improve sight in patients who have limited vision due to RVO.
  • 51. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CRVO CRVO WITH MACULAR ODEMA INVOLVING CENTRE OF RETINA NO OBSERVATION YES INTRAVITREAL AVASTIN . STEROIDS MAY BE CONSIDERED FA OBSERVATION FOR NVE & NVD & NVI ESP IF CNP AREA MORE THAN 10 DD AREANO NVE NVD, NVI NVE,NVD OR NVI PRESENT VITREOUS HGE & NVG PRP + ARC NO GRID LASER
  • 52. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT NVG
  • 53. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Neovascular Glaucoma • Neovascular glaucoma (NVG) is a devastating ocular disease often associated with poor visual prognosis. It is a relatively common complication of several retinal disorders, especially CRVO, PDR , and ocular ischemic syndrome. The pathophysiology of NVG involves the formation of new blood vessels on the surface of the iris and the angle of the anterior chamber, which initially impedes aqueous outflow, but later contracts to produce an angle-closure form of glaucoma.
  • 54. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Neovascular Glaucoma • Currently used medical or surgical treatment has a low success rate, which has been improved by the adjunct use of IVB. The most effective treatment involves retinal ablation, which reduces the level of retinal hypoxia and slows the subsequent angiogenic cascade. The goal of treatment should be to catch disease early and halt the angiogenic cascade to prevent more serious consequences of NVG.
  • 55. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Neovascular Glaucoma • Approximately 36% of NVG occurs after CRVO, 32% with PDR, and 13% occurs after carotid artery obstruction. Given that the underlying etiology of developing NVG is some form of retinal ischemia, it is more prevalent in elderly patients who have significant cardiovascular risk factors such as hypertension, diabetes, dyslipidemia, and a history of smoking.
  • 56. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
  • 57. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT NVG IN CENTRAL RETINAL VEIN OCCLUSION • The predominant risk factor for the development of neovascular complications following central retinal vein occlusion (CRVO) is the extent, location, and duration of retinal ischemia (ischemic drive). Whereas anterior segment neovascularization is rare in nonischemic CRVO, the incidence of NVI is as high as 60% in ischemic eyes, usually occurring at a mean of 3–5 months after the CRVO.
  • 58. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT NVG IN CENTRAL RETINAL VEIN OCCLUSION • The importance of closely following patients with CRVO was demonstrated by the landmark CVOS . The CVOS showed that 15% of nonischemic CRVO could proceed to ischemic CRVO in the first 4 months. During the next 32 months an additional 19% of eyes were found to have converted to the ischemic form for a total of 34% after 3 years.
  • 59. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT NVG IN CENTRAL RETINAL VEIN OCCLUSION •The development of nonperfusion or ischemia was most rapid in the first 4 months and progressed continuously throughout the entire duration of follow-up. NVI of at least two clock hours, and/or NVA developed in 16% of eyes. The CVOS also found that the most important risk factor predictive of rubeosis iridis was poor visual acuity.
  • 60. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT NVG IN CRVO • In a prospective clinical and fluorescein angiographic study of patients with CRVO, 20% developed NVG. The eyes were classified as having either ischemic or hyperpermeable type of CRVO according to the extent of retinal capillary nonperfusion demonstrated by initial fluorescein angiogram. The risk of developing NVG was approximately 60% in eyes with extensive retinal ischemia.
  • 61. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT NVG Etiology and Pathogenesis • In ischemic retinal disease, hypoxia induces production of vascular endothelial growth factor (VEGF), a vasoproliferative substance, which acts upon healthy endothelial cells of viable capillaries to stimulate the formation of fragile new vessels (neovascularization). In cases of extreme retinal hypoxia, there are essentially very few viable retinal capillaries available.
  • 62. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT NVG Etiology and Pathogenesis • In that instance, VEGF is theorized to diffuse forward to the nearest area of viable capillaries, namely the posterior iris. Neovascularization buds off from the capillaries of the posterior iris, grows along the posterior iris, through the pupil, along the anterior surface of the iris, and then into the angle. Once in the angle, the neovascularization, along with its fibrovascular support membrane, acts to both physically block the angle as well as bridge the angle and pull the iris and cornea into apposition, thus blocking the trabecular meshwork.
  • 63. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Diagnosis and Ancillary Testing • Clinicians should perform a comprehensive ophthalmologic exam with particular attention to the pupillary margin . An undilated slit-lamp examination and gonioscopy are essential for the detection of NVI and NVA. Although NVI usually precedes NVA, new vessels may occasionally be found in the angle without evidence of iris neovascularization. Fluorescein angiography of the anterior segment and fluorescein gonio- angiography may be contributive to the diagnosis of early rubeosis iridis .
  • 64. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
  • 65. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
  • 66. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Signs and Symptoms • Depending on the severity of intraocular pressure elevation, intraocular inflammation, and glaucomatous optic neuropathy, patients can present with various signs and symptoms of NVG that include decreased vision, photophobia, corneal edema, conjunctival injection, rubeosis, elevated intraocular pressure, inflammation, hyphema, and vitreous hemorrhage. If the inflammation is severe, or the elevation in IOP is acute, the patient may exhibit severe pain, headache, nausea, and/or vomiting.
  • 67. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Stages of Neovascular Glaucoma • The typical clinical presentation can be divided into three stages: (1) rubeosis iridis; (2) open-angle glaucoma stage; and (3) angle- closure glaucoma stage. These stages generally follow each other in progression. The relevant clinical signs and symptoms are included in this section and summarized in Table .
  • 68. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
  • 69. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT STAGE 1: RUBEOSIS IRIDIS • At this stage tufts of rubeosis can be found at the pupillary margin and/or rubeotic vessels may be found in the angle (Fig. 37-3). Although slit-lamp biomicroscopy can detect iris neovascularization, iris fluorescein angiography has been shown to be more reliable in detecting very early iris neovascularization. Although neovascularization is usually seen first at the peripupillary iris, a thorough gonioscopic examination should be performed since NVA can sometimes precede rubeosis.31 Intraocular pressure is typically normal, but can be elevated if a preexisting open-angle glaucoma is present.
  • 70. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT STAGE 2: OPEN-ANGLE GLAUCOMA • At this stage, the IOP begins to rise and stays elevated. The elevated IOP can also rise suddenly, causing acute-onset glaucoma. Due to the fragile nature of the new vessels, a hyphema can also present at this stage. The degree of rubeosis iridis is usually more prominent and the anterior chamber can show some level of inflammation. Gonioscopy typically shows an open angle, but NVA can be significant.
  • 71. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT STAGE 2: OPEN-ANGLE GLAUCOMA • The NVI can be continuous with the new vessels in the angle. Histopathologically, the hallmark of this stage is growth of a fibrovascular membrane, including rubeotic vessels on the iris surface that extend over the trabecular meshwork, decreasing aqueous outflow and increasing IOP in an aberrantly open angle . Both inflammation in the anterior chamber and possible hyphema can exacerbate the disease process.
  • 72. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT STAGE 3: ANGLE-CLOSURE GLAUCOMA • The contraction of the fibrovascular membrane causes progressive angle closure, ectropion uveae, peripheral anterior synechiae formation, and a flat, glistening appearance to the iris. Patients will often complain of photophobia, reduced visual acuity, acute severe pain, headache, nausea, and/or vomiting. Rubeosis is usually severe, with possible hyphema, moderate inflammation, and IOP as high as 60–70 mmHg. Conjunctival injection and corneal edema are frequently present. Fundoscopic examination may reveal optic nerve cupping. The glaucoma at this stage is severe and usually requires some form of surgical intervention.
  • 73. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
  • 74. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Treatment Options • The treatment of NVG varies depending on the stage of the disease and the clarity of the media. Treatment strategies focus on two separate but related issues: decreasing IOP and reducing retinal ischemic drive.
  • 75. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT TREATMENT OF NEOVASCULARIZATION • Once rubeosis iridis has begun, the primary goal of treatment is to reduce the ischemic drive of neovascularization. This is best accomplished with panretinal photocoagulation (PRP) to destroy ischemic retina, minimize the eye’s oxygen demand, and reduce the amount of VEGF being released. PRP tends to be effective in causing regression and involution of anterior segment neovascularization.
  • 76. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT TREATMENT OF NEOVASCULARIZATION • In recent years, bevacizumab (Avastin [Genentech, Inc.]) has emerged as an adjunct first-line treatment for rubeosis iridis. Initial studies reported rapid regression of iris and angle neovascularization in patients with NVG and refractory IOP elevation . In the first large study using IVB, Wakabayashi et al. showed that IVB combined with full PRP in patients with rubeosis iridis may reduce risk of developing NVG. IVB stabilized neovascular activity, and may help control IOP if the angle is still open. If the angle was closed secondary to synechiae, there was no effect on IOP.
  • 77. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Slit-lamp photograph before use of Avastin in a patient with NVG
  • 78. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT fluorescein photograph before use of Avastin in a patient with NVG
  • 79. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Slit-lamp photograph after use of Avastin in a patient with NVG
  • 80. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT fluorescein photograph after use of Avastin in a patient with NVG
  • 81. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
  • 82. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT TREATMENT OF NVG
  • 83. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT TREATMENT OF NVG • Once a patient has progressed beyond the early stages of rubeosis iridis and has elevated IOP with an open- or closed- angle glaucoma, the primary goals of treatment are to regress any neovascularization as described above and control IOP.
  • 84. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Medical Management of IOP • If the angle is open and the eye still has relatively useful vision, but IOP is above normal, initiate medical therapy to reduce aqueous production. Patients may require a combination of carbonic anhydrase inhibitors (topical or systemic), topical β- blockers, and/or α2-agonists to control IOP. Prostaglandin analogues are generally not recommended since there is compromised access to the uveoscleral route. In addition, anti- inflammatory agents such as topical steroid drops and cycloplegic agents may be indicated to control any inflammation and pain.
  • 85. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Surgical Management of IOP • Occasionally, although the angle is open, it may not be possible to control IOP on medical management alone. Surgical glaucoma intervention involving filtering surgery, drainage implants, and/or cyclodestructive procedures may be necessary. The majority of patients with NVG eventually need surgical intervention to control elevated IOP. In one review, 80% of patients, if followed long enough, needed glaucoma surgery for elevated IOP, regardless of prior treatment .
  • 86. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Filtering Surgery • Filtering surgery is relatively effective in controlling elevated IOP associated with NVG, but is at risk for failure due to severe ocular inflammation. Results from two studies involving early trabeculectomy with mitomycin C (MMC) have shown successful IOP control of 53% at 13 months50 and 66.7% at 28 months.51 Another study in which trabeculectomy with MMC was performed on eyes with active NVG secondary to PDR showed success rates of 67% at 1 year and 61.8% after 2–3 years
  • 87. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Mitomycin MMC soaked sponges are used for intraoperative application
  • 88. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT (M) Subconjunctival application of mitomycin C. • (M1) Antimetabolites are especially important on filter revisions where there is increased tendency for scarring. Notice the pledget is pushed posteriorly to the premade subconjunctival pocket
  • 89. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT (M) Subconjunctival application of mitomycin C. • M2) This drawing shows the typical placement pattern for the sponges, three in this case. The authors prefer this placement pattern for fornix or limbal filters. Currently, the pledgets are placed posteriorly in order to encourage flow away from the limbus. Excessive flow directly over the fistula is more likely to cause the bleb to become pale and avascular. The dose is 0.4 mg/mL for 4 minutes for NVG. When performing a combined cataract and trabeculectomy, one may consider increasing the MMC exposure time and/or concentration. After the MMC is removed, the area is profusely irrigated.
  • 90. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Filtering Surgery • The success rate has improved with performing adequate PRP prior to surgery . When IVB was given preoperatively to eyes that subsequently underwent trabeculectomy with MMC, patients experienced decreased hyphema and increased surgical success. At six months, 95% of IVB eyes achieved complete success, whereas in the trabeculectomy with MMC group only 50% achieved complete success and 75% had qualified success, meaning they still required topical and/or oral medications to control IOP.
  • 91. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Drainage Implants • Aqueous tube shunt implants have some success in the treatment of refractory NVG, especially in situations where conventional filtering surgery has failed.57,58 Many practitioners prefer using glaucoma drainage implants (GDIs) because they are less dependent on control of intraocular inflammation and failure of the filtering bleb. Although the initial response to Ahmed valve and Molteno implants is relatively good, the long-term outcome is poor.
  • 92. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT AGV contains a valve mechanism which must be primed prior to insertion.
  • 93. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Drainage Implants • Young patients with poor preoperative visual acuity are at risk of surgical failure. NVG itself is a risk factor for Ahmed valve failure and worse visual prognosis.61 Use of adjunct IVB with aqueous shunt implants has been shown to be successful. In a study that included 56 eyes that received IVB and PRP for NVG, those that required subsequent incisional surgery were less inflamed and had lower intraoperative and post-operative hemorrhage.62 This study also confirmed previous findings that most patients with NVG, if followed long enough, require surgical in
  • 94. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Cyclodestructive Procedures • Cyclodestruction to reduce production of aqueous humor can be achieved with photocoagulation or cryotherapy. Long-term results of noncontact neodymium : yttrium–aluminum–garnet cyclophotocoagulation in neovascular glaucoma showed success rates of 65%, 49.8%, and 34.8% at 1-, 3-, and 6-year follow-up, respectively. Contact transscleral diode cyclophotocoagulation is effective in lowering IOP in eyes with neovascular glaucoma.
  • 95. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT Cyclodestructive Procedures • However these procedures are not without risk, including hypotony, phithisis, and vision loss. Currently, a standardized cyclophotocoagulation protocol in NVG has not yet been established. Although the IOP can often be controlled, visual outcomes are typically very poor, with the rate of long-term visual loss in patients who have NVG approaching nearly 50%.
  • 96. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT TREATMENT OF LATE STAGES OF NEOVASCULAR GLAUCOMA • If the eye no longer has visual potential, it is recommended to initiate medical therapy to control IOP, including cycloplegic agents, steroid drops for comfort, PRP if the media is clear and IVB. If the media is cloudy, then panretinal cryotherapy and cyclodestructive surgery to control IOP will likely be needed. In a study of 70 patients with NVG resistant to medical and surgical treatment that were treated with transconjunctival cyclocryocoagulation, there was a significant decrease in IOP and eye pain after 180 days.
  • 97. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT TREATMENT OF LATE STAGES OF NEOVASCULAR GLAUCOMA • However, if the eye has no vision and medical therapy is not controlling the pain and discomfort, more aggressive action may be needed such as performing retrobulbar alcohol injection, evisceration, or enucleation.
  • 98. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CONCLUSION • CRVO is a sight-threatening disease with significant ocular morbidity, including macular edema and ocular neovascularization. Before the recent advent of intravitreal pharmacotherapy in the management of CRVO, standard of care was guided by results from the CVOS, which recommended observation of macular edema and retinal ischemia with management of neovascular sequelae using PRP. In the absence of robust treatment options for CRVO,50 other approaches, including the administration of r-tPA, creation of CRA, and various surgical interventions, had been reported with variable success and often unacceptable adverse effects.
  • 99. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CONCLUSION • More recently, intravitreal corticosteroids and particularly anti-VEGF agents have demonstrated impressive improvements in macular edema, visual acuity, and even neovascular complications with a favorable side-effect profile. The use of ranibizumab (Lucentis) and a sustained- release dexamethasone implant (Ozurdex) have been FDA- approved for the treatment of CRVO. Intravitreal pharmacotherapy has now replaced observation as standard of care for management of macular edema associated with CRVO.
  • 100. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT CRVO CRVO WITH MACULAR ODEMA INVOLVING CENTRE OF RETINA NO OBSERVATION YES INTRAVITREAL AVASTIN . STEROIDS MAY BE CONSIDERED FA OBSERVATION FOR NVE & NVD & NVI ESP IF CNP AREA MORE THAN 10 DD AREANO NVE NVD, NVI NVE,NVD OR NVI PRESENT VITREOUS HGE & NVG PRP + ARC NO GRID LASER
  • 101. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT
  • 102. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT THANK YOU DR DINESH DR SONALEE
  • 103. INTRODUCTION CLINICAL PICTURE DIAGNOSIS COMPLICATION TREATMENT